Processa Pharmaceuticals Inc logo

PCSAProcessa Pharmaceuticals Inc

NASDAQ · Healthcare · Biotechnology

$2.06

+$0.01 (+0.49%)

Processa Pharmaceuticals Inc (PCSA) is a biotechnology company listed on NASDAQ. It is led by George K. Ng Esq., J.D., based in 601 21st Street, Vero Beach, FL, United States, 32960, with about 12 employees. Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.

Net income was -$3.4M. PCSA currently screens at market cap $5.9M.

Use this PCSA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PCSA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PCSA SEC filings page. Lician reads the product cache first so this HTML stays unique to Processa Pharmaceuticals Inc even when a live quote feed is slow.

About Processa Pharmaceuticals Inc

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.

PCSA Key Statistics

Market Cap

$5.91M

Volume

42,522

Previous Close

$2.17

Day Range

$2.15$2.28

0

P/B Ratio

2.27

EPS

-$3.87

Revenue

$0.00

Net Income

-$11.85M

Gross Profit

$0.00

Free Cash Flow

$0.00

Employees

12

PCSA Financials

Annual income statement in USD. Latest reported periods first.

PCSA annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$0.00$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income-$11.85M-$11.12M-$27.42M-$11.43M
EPS (Diluted)-$3.87-$8.48-$34.05$0.00

Total Assets

$3.23M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$1.19M

Operating Cash Flow

-$11.25M

Free Cash Flow

$0.00

Processa Pharmaceuticals Inc Company Information

CEO & Director
George K. Ng Esq., J.D.
Headquarters
601 21st Street, Vero Beach, FL, United States, 32960
Phone
772 453 2899
IPO / Founded
2017-10-10
Industry
Biotechnology
Data Updated:

Upcoming Events for PCSA